TABLE 1.

Patient demographics and pharmacokinetic and pharmacodynamic parametersa

ParameterValue for group:
123
CLCR criterion (ml/min)>10060-10011-59
Dose2 g q122 g q121-2 g q24b
N121212
Age (yr)c39 ± 1257 ± 15d69 ± 14d
Race (no. of AA/C/O)6/6/08/3/110/2/0
Gender (no. of M/F)10/28/47/5
APACHE II scoree8 (0-15)15 (2-23)12.5 (5-32)
CLCR (ml/min)c122 ± 1880 ± 11d35 ± 13d
Cmax (mg/liter)c259 ± 287167 ± 124207 ± 295
Cmin (mg/liter)c3.3 ± 3.619.5 ± 21.5d14.0 ± 11.5d
t1/2 (h)c3.1 ± 2.67.6 ± 5.2d12.1 ± 6.3d
CL (liters/h)e7.0 ± 4.34.4 ± 2.22.6 ± 1.1d
Vss (liters/kg)c0.28 ± 0.250.46 ± 0.300.56 ± 0.30d
AUC24 (mg · h/liter)e734 ± 3441,138 ± 540d845 ± 296
Cmin ≥ MIC50 (no. of patients)611d11d
Cmin ≥ 8 mg/liter (no. of patients)18d7d
  • a AA, African American; C, Caucasian; O, other; M, male; F, female; Vss, volume of distribution at steady state.

  • b Two grams q24 when CLCR was ≥30 but <60 ml/min and 1 g q24 when CLCR was >10 but <30 ml/min.

  • c Mean and standard deviation.

  • d The P value was < 0.05 in a comparison with the result obtained with a CLCR of > 100 ml/min.

  • e Median (range) APACHE II score at the start of cefepime therapy.